ulrich medical USA, the pioneer in expandable corpectomy devices and a market leader in spine technology, announced FDA clearance for expanded indications of the Momentum and Momentum MIS Posterior Spinal Fixation Systems. The expanded indications allow for both Momentum and Momentum MIS systems to be used in conjunction with G21 V-STEADY Radiopaque Bone Cement to help restore the integrity of the spinal column in patients with advanced stage tumors.
“I’m excited that I can now use Momentum in conjunction with V-STEADY,” said Alekos Theologis, MD, Assistant Professor of Orthopedic Spine Surgery at UCSF Health. “Momentum has been a valuable treatment option and this enhancement will be beneficial to a segment of my patients.”
Also Read : AMETEK Completes Acquisition of Paragon Medical
The Momentum and Momentum MIS Posterior Spinal Fixation Systems are used to provide stabilization, fixation and correction of the thoracolumbar and sacroiliac spine. These fixation systems enable surgeons to manage a comprehensive range of adult degenerative and deformity cases, including connections from occiput to pelvis, bone cement augmentation, and revisions for adjacent segment disease in restoration of spinal alignment in open or percutaneous procedures.
“We are pleased to have received this expanded indication from the FDA”, said Eric Lucas, Ph.D., Vice President of Technology at ulrich medical USA. “The combination of Momentum with V-STEADY offers our surgeon customers a new treatment option to support their most challenging patients.”
SOURCE : PRNewswire